**QIAGEN announces appointment of new Supervisory Board member**

* **Dr. Toralf Haag appointed to Supervisory Board and a member of the Audit Committee**

**Venlo, the Netherlands, January 8, 2021 –** QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that Dr. Toralf Haag has been appointed a member of the Supervisory Board with immediate effect. He will also become a member of the Audit Committee.

Dr. Haag was chosen as part of an expansion process launched by the Supervisory Board to further complement and enhance the Board’s already extensive experience in Life Sciences and diagnostics. The addition of Dr. Haag brings the number of current Supervisory Board members to seven.

“We are pleased to welcome Dr. Toralf Haag to our Supervisory Board. This appointment further deepens our expertise and experience in the Life Sciences and diagnostics,” said Lawrence Rosen, Chairman of the Supervisory Board. “This appointment of Dr. Haag is also one of the actions to come out of a review process we initiated during 2020. The Supervisory Board reaffirms its commitment to the highest level of excellence in corporate governance and working effectively with the management team to create value for QIAGEN’s stakeholders, including its shareholders.”

Dr. Haag has served since October 2018 as Chairman of the Corporate Board of Management of Voith GmbH & Co. KGaA in Germany, a global technology company with more than EUR 4 billion in annual sales and over 19,000 employees. Before joining Voith in October 2016 as Chief Financial Officer, he served for more than 11 years as CFO and Member of the Executive Committee of Lonza Group AG since August 2005. Dr. Haag began his career in 1994 as the personal assistant to the CEO of Thyssen Handelsunion AG after earning a degree in Business Administration from the University of Augsburg and a Ph.D. at the University of Kiel.

**About QIAGEN**

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2020, QIAGEN employed more than 5,300 people in over 35 locations worldwide. Further information can be found at <http://www.qiagen.com>.

**Forward-Looking Statement**

*Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.*

**Contacts**

John Gilardi

Vice President Corporate Communications and Investor Relations

+49 2103 29 1171 and +49 152 018 11711 and +1 240 686 2222 / [john.gilardi@qiagen.com](mailto:john.gilardi@qiagen.com)

Phoebe Loh

Director Investor Relations

+49 2103 29 11457 / [phoebe.loh@qiagen.com](mailto:phoebe.loh@qiagen.com)

Dr. Thomas Theuringer

Senior Director, Head of External Communications

+49 2103 29 11826 / [thomas.theuringer@qiagen.com](mailto:thomas.theuringer@qiagen.com)

Robert Reitze

Senior Manager Public Relations

+49 2103 29 11676 / [robert.reitze@qiagen.com](mailto:robert.reitze@qiagen.com)